Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice.

Mastino A, Favalli C, Grelli S, Rasi G, Pica F, Goldstein AL, Garaci E

International journal of cancer1 Feb 1992Cited by 38 (Europe PMC)

PMID1735618DOI10.1002/ijc.2910500327PepBankPUB-01735618

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

01AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice with Lewis lung carcinoma, thymosin alpha‑1 plus IL-2 given after cyclophosphamide induced complete tumor regression in all mice studied.
In plain wordsIn mice with lung cancer, thymosin alpha‑1 plus IL-2 after chemotherapy cleared the tumour in all mice studied.
Peptide
Thymosin alpha-1
Outcome
DecreaseComplete tumor regression
Study
mousen: not reported in source
C57Bl/6NCrlBR mice with Lewis lung carcinoma
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Combined administration of T alpha 1 plus IL-2, after CY treatment, was much more effective than use of each biological response modifier (BRM) alone, and induced complete tumor regression in all of the mice studied.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study we have investigated the effects of thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2), singly or in combination with cyclophosphamide (CY), on tumor growth, survival and cytotoxicity in C57Bl/6NCrlBR mice with Lewis lung carcinoma (3LL).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-0173561801
02AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice with Lewis lung carcinoma, thymosin alpha‑1 plus IL-2 after cyclophosphamide was much more effective than each biological response modifier alone.
In plain wordsIn mice with lung cancer, thymosin alpha‑1 plus IL-2 after chemotherapy worked much better than either one alone.
Peptide
Thymosin alpha-1
Outcome
DecreaseTumor response of combination versus each agent alone
Study
mousen: not reported in source
C57Bl/6NCrlBR mice with Lewis lung carcinoma
Comparator
Thymosin alpha 1 alone; IL-2 alone
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Combined administration of T alpha 1 plus IL-2, after CY treatment, was much more effective than use of each biological response modifier (BRM) alone
1 context sentence(design, population, supporting numbers)
Summary · context
In this study we have investigated the effects of thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2), singly or in combination with cyclophosphamide (CY), on tumor growth, survival and cytotoxicity in C57Bl/6NCrlBR mice with Lewis lung carcinoma (3LL).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-0173561802
03AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice with Lewis lung carcinoma, thymosin alpha‑1 plus IL-2 without cyclophosphamide only slightly reduced the rate of tumor growth.
In plain wordsIn mice with lung cancer, thymosin alpha‑1 plus IL-2 without chemotherapy slowed tumour growth only slightly.
Peptide
Thymosin alpha-1
Outcome
DecreaseTumor growth rate with combination immunotherapy without cyclophosphamide
Study
mousen: not reported in source
C57Bl/6NCrlBR mice with Lewis lung carcinoma
Outcome group
Tumor growth · Cancer
Source sentences
Summary
Combination immunotherapy alone without CY only slightly reduced the rate of tumor growth
1 context sentence(design, population, supporting numbers)
Summary · context
In this study we have investigated the effects of thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2), singly or in combination with cyclophosphamide (CY), on tumor growth, survival and cytotoxicity in C57Bl/6NCrlBR mice with Lewis lung carcinoma (3LL).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-0173561803
04AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism
In mice with Lewis lung carcinoma, thymosin alpha‑1 plus IL-2 and cyclophosphamide increased the cytotoxicity of spleen cells.
In plain wordsIn mice with lung cancer, thymosin alpha‑1 plus IL-2 and chemotherapy increased the killing activity of spleen cells.
Peptide
Thymosin alpha-1
Outcome
IncreaseCytotoxicity of spleen cells
Study
mousen: not reported in source
C57Bl/6NCrlBR mice with Lewis lung carcinoma
Outcome group
Immune response · Cancer
Source sentences
Summary
Combined chemo-immunotherapy also increased the cytotoxicity of spleen cells
1 context sentence(design, population, supporting numbers)
Summary · context
In this study we have investigated the effects of thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2), singly or in combination with cyclophosphamide (CY), on tumor growth, survival and cytotoxicity in C57Bl/6NCrlBR mice with Lewis lung carcinoma (3LL).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-0173561804
05AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome
In mice with Lewis lung carcinoma, thymosin alpha‑1 plus IL-2 and cyclophosphamide markedly enhanced long-term survival in all treated animals.
In plain wordsIn mice with lung cancer, thymosin alpha‑1 plus IL-2 and chemotherapy greatly improved long-term survival in all treated animals.
Peptide
Thymosin alpha-1
Outcome
IncreaseLong-term survival
Study
mousen: not reported in source
C57Bl/6NCrlBR mice with Lewis lung carcinoma
Outcome group
Mortality · Cancer
Source sentences
Summary
markedly enhanced long-term survival in all treated animals.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study we have investigated the effects of thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2), singly or in combination with cyclophosphamide (CY), on tumor growth, survival and cytotoxicity in C57Bl/6NCrlBR mice with Lewis lung carcinoma (3LL).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-0173561805
06AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism
In mice with Lewis lung carcinoma, depletion of immune cells by irradiation or antibodies against T cells or NK cells abolished the positive response to the combination therapy.
In plain wordsIn mice with lung cancer, removing immune cells cancelled the benefit of the combination treatment.
Peptide
Thymosin alpha-1
Outcome
DecreaseResponse to combination therapy after immune cell depletion
Study
mousen: not reported in source
C57Bl/6NCrlBR mice with Lewis lung carcinoma
Outcome group
Immune response · Cancer
Source sentences
Summary
Depletion of immune cells, using either total-body sub-lethal irradiation (400 rads) or antibodies directed against T-cell (anti-CD4 and CD8) or NK-cell (anti-asialo GM1) populations, abolished the positive response to combination therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study we have investigated the effects of thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2), singly or in combination with cyclophosphamide (CY), on tumor growth, survival and cytotoxicity in C57Bl/6NCrlBR mice with Lewis lung carcinoma (3LL).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-0173561806
07AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Mechanism
In mice with Lewis lung carcinoma, tumors from the combination chemo-immunotherapy group showed many infiltrating lymphoid cells around a circumscribed area of necrosis.
In plain wordsIn mice with lung cancer, tumours treated with the combination contained many immune cells around dead tissue.
Peptide
Thymosin alpha-1
Outcome
Not applicableTumor histology after combination chemo-immunotherapy
Study
mousen: not reported in source
C57Bl/6NCrlBR mice with Lewis lung carcinoma
Outcome group
Immune response · Cancer
Source sentences
Summary
Histological analysis of the tumors obtained from mice treated with combination chemo-immunotherapy revealed a high number of infiltrating lymphoid cells surrounding a well-circumscribed area of necrosis consisting solely of dead cells.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study we have investigated the effects of thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2), singly or in combination with cyclophosphamide (CY), on tumor growth, survival and cytotoxicity in C57Bl/6NCrlBR mice with Lewis lung carcinoma (3LL).
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-0173561807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice.

Summary

Results from this study7

Studies that did not test the peptide alone7

Version history

Subjects

Publication types

MeSH terms